Provided are body fluid management systems for patient care that include, in operable combination, a control system assembly comprising a fluid flow detection and control subassembly, a user data interface, a patient interface assembly comprising a wearable pressure sensor subassembly having a pressure sensor in the path of said body fluid for attaching directly to a patient proximate to an anatomical marker and an orientation sensor to monitor and/or control the pressure and/or flowrate of a body fluid such as cerebrospinal fluid, blood, or urine.

A method to regulate patient gene expression by controllably circulating antisense oligonucleotide material (ASO) through a closed fluid circuit formed between the patient's ventricle and lumbar regions. To that end, after coupling a fluid channel between those regions, such embodiments add ASO to the fluid channel (preferably after the channel is primed with CSF) and energize a pump to controllably flow the CSF and the ASO mixed with the CSF. CSF/ASO fluid flow may be managed to localize treatment (e.g., providing deep brain distribution) while minimizing toxicity potentially caused by the ASO to certain nerves (e.g., the peripheral nerve).

Cerebrospinal fluid (CSF) and other fluid amelioration systems completely or partially implantable within a mammalian subject and associated methods include a substrate and an agent for amelioration of a toxic biomolecule present in the CSF or fluid, wherein the agent is disposed on or within the substrate.

A CSF management method for use with a patient forms a closed loop CSF circuit between two points on the patient's body. The CSF circuit has a therapeutic inlet to receive a therapeutic material (e.g. a drug), and a pump having a pump outlet to direct CSF along the CSF circuit. The method controls the pump to direct CSF from the pump outlet at a CSF rate that is different from the natural flow rate (i.e., the natural CSF flow rate). The therapeutic material is added to the CSF via the therapeutic input at a therapeutic rate. The CSF rate is different than the therapeutic rate and/or may be greater than the therapeutic rate. Alternative methods may control a bolus drug infusion to localize the application to a target region.

A CSF management method for use with a patient forms a closed loop CSF circuit between two points on the patient's body. The CSF circuit has a therapeutic inlet to receive a therapeutic material (e.g. a drug), and a pump having a pump outlet to direct CSF along the CSF circuit. The method controls the pump to direct CSF from the pump outlet at a CSF rate that is different from the natural flow rate (i.e., the natural CSF flow rate). The therapeutic material is added to the CSF via the therapeutic input at a therapeutic rate. The CSF rate is different than the therapeutic rate and/or may be greater than the therapeutic rate. Alternative methods may control a bolus drug infusion to localize the application to a target region.

A CSF management method for use with a patient forms a closed loop CSF circuit between two points on the patient's body. The CSF circuit has a therapeutic inlet to receive a therapeutic material (e.g. a drug), and a pump having a pump outlet to direct CSF along the CSF circuit. The method controls the pump to direct CSF from the pump outlet at a CSF rate that is different from the natural flow rate (i.e., the natural CSF flow rate). The therapeutic material is added to the CSF via the therapeutic input at a therapeutic rate. The CSF rate is different than the therapeutic rate and/or may be greater than the therapeutic rate. Alternative methods may control a bolus drug infusion to localize the application to a target region.

A catheter system includes abase plate having a bottom surface, an outer circumferential wall, a circular flange extending inwardly from the outer circumferential wall, and an inner ring that is spaced apart from the outer circumferential wall, extends upwardly from the bottom surface, and defines a central opening in the base plate. A catheter is placed within the central opening of the base plate. A cover is placed over and secured to the base plate. The cover has a closed upper portion defining an internal chamber of the cover and a lower portion defining an opening in the cover. The lower portion includes a skirt with a flange extending outwardly around a periphery of the skirt to engage the circular flange of the base plate and form a closed reservoir. Methods of accessing cerebrospinal fluid using the catheter systems are also provided.

Provided are body fluid management systems for patient care that include, in operable combination, a control system assembly comprising a fluid flow detection and control subassembly, a user data interface, a patient interface assembly comprising a wearable pressure sensor subassembly having a pressure sensor in the path of said body fluid for attaching directly to a patient proximate to an anatomical marker and an orientation sensor to monitor and/or control the pressure and/or flowrate of a body fluid such as cerebrospinal fluid, blood, or urine.

A method and system for treating Alzheimer's disease wherein blood, spinal fluid or brain cavity fluid is circulated into and outside of the body by means of blood pumps or other external circulatory systems. While passing through the pumping system, the amyloid plaques and tau tangles are filtered from the fluids and returned to the body lowering the protein levels, and in the process, reduce symptoms. In one embodiment a patient's blood is filtered using a pump to circulate the blood from the patient to the collection vessel where an electrical current will cause anything that has a positive charge to be attracted to a cathode plate suspended in the collection vessel for later disposal. In an alternate embodiment a patient's brain and/or spinal fluid a pump operates to circulate a flushing fluid. The pump will circulate the solution from the collection vessel to the patient.

Disclosed herein, are compositions, methods, systems, and apparatus for collecting biological material from the nasal cavity of a subject or the olfactory region of a subject's nasal cavity. In some embodiments, the biological material is collected from a targeted sub-region of the nasal cavity, such as a targeted sub-region of the olfactory region, wherein such biological material is specific to the targeted sub-region. In some embodiments, the biological material collected from a targeted sub-region is preserved according to its localization. In some embodiments, the biological material comprises cerebrospinal fluid, one or more microbes of the patient's microbiome, one or more components of the patient's metabolome, one or more pathogens, and/or one or more biomarkers of interest. In some embodiments, a specific formulation is delivered to the region in the nasal cavity for facilitating biological material collection located therein.